Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajesh Malik

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Journal of Vascular Surgery|March 9, 2010
Five-year results for the Talent enhanced Low Profile System abdominal stent graft pivotal trial including early and long-term safety and efficacyIrene C Turnbull, Frank J Criado, Luis Sanchez, et al.
Journal of Vascular Surgery|March 30, 2010
Outcome of elective endovascular abdominal aortic aneurysm repair in octogenarians and nonagenariansStuart B Prenner, Irene C Turnbull, Rajesh Malik, et al.
Future Oncology (London, England)|September 22, 2022
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2Shom Goel, Antoinette R Tan, Hope S Rugo, et al.
Cancer Management and Research|August 19, 2021
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled StudiesMaen Hussein, Marina Maglakelidze, Donald A Richards, et al.
Vascular and Endovascular Surgery|September 12, 2008
Early results for below-knee bypasses using DistafloIosif Gulkarov, Rajesh Malik, Rakhsim Yakubov, et al.
Immunopharmacology and Immunotoxicology|February 6, 2014
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patientsJonathan W Riess, Nupur Bhattacharya, Kim R M Blenman, et al.
Critical Care Medicine|February 22, 2013
A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsisKalpalatha Guntupalli, Nathan Dean, Peter E Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapyPurvish M Parikh, Ashok Vaid, Suresh H Advani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancerRaghunadharao Digumarti, Yenyun Wang, Ganapathi Raman, et al.
Science Translational Medicine|April 28, 2017
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustionShenghui He, Patrick J Roberts, Jessica A Sorrentino, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Journal of Vascular Surgery|March 9, 2010
Five-year results for the Talent enhanced Low Profile System abdominal stent graft pivotal trial including early and long-term safety and efficacyIrene C Turnbull, Frank J Criado, Luis Sanchez, et al.
Journal of Vascular Surgery|March 30, 2010
Outcome of elective endovascular abdominal aortic aneurysm repair in octogenarians and nonagenariansStuart B Prenner, Irene C Turnbull, Rajesh Malik, et al.
Future Oncology (London, England)|September 22, 2022
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2Shom Goel, Antoinette R Tan, Hope S Rugo, et al.
Cancer Management and Research|August 19, 2021
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled StudiesMaen Hussein, Marina Maglakelidze, Donald A Richards, et al.
Vascular and Endovascular Surgery|September 12, 2008
Early results for below-knee bypasses using DistafloIosif Gulkarov, Rajesh Malik, Rakhsim Yakubov, et al.
Immunopharmacology and Immunotoxicology|February 6, 2014
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patientsJonathan W Riess, Nupur Bhattacharya, Kim R M Blenman, et al.
Critical Care Medicine|February 22, 2013
A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsisKalpalatha Guntupalli, Nathan Dean, Peter E Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapyPurvish M Parikh, Ashok Vaid, Suresh H Advani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancerRaghunadharao Digumarti, Yenyun Wang, Ganapathi Raman, et al.
Science Translational Medicine|April 28, 2017
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustionShenghui He, Patrick J Roberts, Jessica A Sorrentino, et al.
Pageof 7